Back to Search Start Over

Increased Frequency of TOX+ CD39+ TIGIT+ CD73- CD8+ T Cells in Patients with Newly Diagnosed AML

Authors :
Brauneck, Franziska
Ackermann, Christin
Wildner, Nils
Wellbrock, Jasmin
Bokemeyer, Carsten
Schulze zur Wiesch, Julian
Fiedler, Walter
Source :
Blood; November 2020, Vol. 136 Issue: Supplement 1 p36-36, 1p
Publication Year :
2020

Abstract

Brauneck: Daiichi Sankyo: Consultancy, Honoraria, Other: support for meeting attendance; Novartis: Other: support for meeting attendance; Jazz Pharmaceuticals: Other: support for meeting attendance. Bokemeyer:Merck KGaA: Honoraria; Janssen-Cilag: Research Funding; Roche: Honoraria, Research Funding; Bayer: Honoraria, Research Funding; Taiho Pharmaceutical: Research Funding; Pfizer: Other; Karyopharm Therapeutics: Research Funding; Millenium: Research Funding; MSD: Research Funding; Nektar: Research Funding; Novartis: Research Funding; Rafael Pharmaceuticals: Research Funding; Springworks Therapeutics: Research Funding; Sanofi: Consultancy, Honoraria, Other: travel accomodations; Bristol-Myers Squibb: Honoraria, Other: travel accomodations, Research Funding; AstraZeneca: Honoraria, Research Funding; Merck Sharp & Dohme: Consultancy, Honoraria; Lilly/ImClone: Consultancy, Research Funding; Merck Serono: Consultancy, Other: travel accomodations; Bayer Schering Pharma: Consultancy; GSO: Consultancy; AOK Health Insurance: Consultancy; Abbvie: Research Funding; ADC Therapeutics: Research Funding; Agile Therapeutics: Research Funding; Alexion Pharmaceuticals: Research Funding; Amgen: Research Funding; Apellis Pharmaceuticals: Research Funding; Astellas: Research Funding; BerGenBio: Research Funding; Blueprint Medicines: Research Funding; Boehringer Ingelheim: Research Funding; Celgene: Research Funding; Daiichi Sankyo: Research Funding; Eisai: Research Funding; Gilead Sciences: Research Funding; Glycotope GmbH: Research Funding; GSK: Research Funding; Incyte: Research Funding; IO Biotech: Research Funding; Isofol Medical: Research Funding. Fiedler:Amgen: Consultancy, Honoraria, Other: support for meeting attendance, Patents & Royalties, Research Funding; ARIAD/Incyte: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees; Morphosys: Consultancy, Honoraria; Abbvie: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Honoraria, Other: support for meeting attendance; Gilead: Other: support for meeting attendance; Daiichi Sankyo: Other: support for meeting attendance.

Details

Language :
English
ISSN :
00064971 and 15280020
Volume :
136
Issue :
Supplement 1
Database :
Supplemental Index
Journal :
Blood
Publication Type :
Periodical
Accession number :
ejs54555728
Full Text :
https://doi.org/10.1182/blood-2020-139917